Genmab A/S Stock

Genmab A/S Equity Ratio

The Equity Ratio of Genmab A/S (GMAB.CO) as of Aug 13, 2026 is 45.42 %. In the previous year, Equity Ratio was 80.11 % — a change of -43.30% (lower).

Equity Ratio

45.42 %

YoY

-43.30%

Last updated:

Equity Ratio of Genmab A/S is 2026 45.42 % . Equity Ratio of Genmab A/S was 2025 80.11 % . It decreases by -43.30% lower compared to the previous year.
Access this data via the Eulerpool API
Get Free API Key

Genmab A/S Stock analysis

What does Genmab A/S do? Genmab A/S is a Danish biotechnology company specializing in the discovery and development of antibody therapies for cancer and other serious diseases. The company was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmab A/S stock

Equity Ratio of Genmab A/S is 45.42 % in 2026.

Equity Ratio of Genmab A/S changed from 80.11 % to 45.42 %, representing a -43.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Genmab A/S since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Genmab A/S with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Leverage — Genmab A/S

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Genmab A/S